President Donald Trump said Monday that there is a relationship between the use of the popular free sale analgesic Tylenol with the development of autism during pregnancyan affirmation that many doctors question.
The researchers affirm that there is no conclusive evidence that there is a relationship between the use of Tylenol and autism. They claim that leucovorina, used to treat some cancer patients who receive chemotherapy, He has shown promising results in very small essays, but which are still needed on a large scale.
Trump also suggested leucovorina, a form of folic acid, as a treatment for autism symptoms during an event in the White House.
The Food and Medicines Administration, FDA, published a notice in the Federal Registry before its speech, in which it approved a version of the medication manufactured by GSK that had previously retired. LA FDA approved the medicine for an autism -related condition.
FDA cited a review of the use of leucovorine in 40 patients with an unusual metabolic disorder called folate brain deficiency that can cause a series of neurological symptoms, some of which are observed in people with autism.
The FDA will notify doctors that the use of Tylenol during pregnancy may be associated with a very high risk of autism, Trump said, without presenting evidence to support this statement.
“Tylenol is not good. I say it clearly. It’s not good,” he said. “You should not give tylenol to children every time they put a vaccine,” he added.
The Secretary of Health, Robert F. Kennedy Jr., has promised to find the cause of autism and has been suggesting without scientific evidence that is related to vaccines. He has also said that he must be related to an environmental toxin.
Decades of studies have not yet established a definitive cause, but many scientists believe that genetics, potentially in combination with environmental influences, plays a role.
Many experts, including centers for disease control and prevention, largely attribute the increase in autism rate to generalized detection and inclusion of a broader range of behaviors to define the condition, which leads to the diagnosis of individuals with milder or more subtle signs of the condition.
